Ovarian cancer, version 1.2019 featured updates to the nccn guidelines

Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Jonathan S. Berek, Lee May Chen, Mihaela Cristea, Marie DeRosa, Adam C. ElNaggar, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Angela Jain, Charles A. Leath, Joyce Liu, Haider Mahdi, Daniela Matei, Michael McHaleKaren McLean, David M. O'Malley, Richard T. Penson, Sanja Percac-Lima, Elena Ratner, Steven W. Remmenga, Paul Sabbatini, Theresa L. Werner, Emese Zsiros, Jennifer L. Burns, Anita M. Engh

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living >5 years fromdiagnosis. Amajor challenge in treating ovarian cancer is that most patients have advanced disease at initial diagnosis. The best outcomes are observed in patients whose primary treatment includes complete resection of all visible disease plus combination platinum-based chemotherapy. Research efforts are focused on primary neoadjuvant treatments that may improve resectability, as well as systemic therapies providing improved long-term survival. These NCCN Guidelines Insights focus on recent updates to neoadjuvant chemotherapy recommendations, including the addition of hyperthermic intraperitoneal chemotherapy, and the role of PARP inhibitors and bevacizumab as maintenance therapy options in select patients who have completed primary chemotherapy.

Original languageEnglish (US)
Pages (from-to)896-909
Number of pages14
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume17
Issue number8
DOIs
StatePublished - Jan 1 2019

Fingerprint

Ovarian Neoplasms
Guidelines
Drug Therapy
Neoadjuvant Therapy
Platinum
Cause of Death
Therapeutics
Survival
Research
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Armstrong, D. K., Alvarez, R. D., Bakkum-Gamez, J. N., Barroilhet, L., Behbakht, K., Berchuck, A., ... Engh, A. M. (2019). Ovarian cancer, version 1.2019 featured updates to the nccn guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 17(8), 896-909. https://doi.org/10.6004/jnccn.2019.0039

Ovarian cancer, version 1.2019 featured updates to the nccn guidelines. / Armstrong, Deborah K.; Alvarez, Ronald D.; Bakkum-Gamez, Jamie N.; Barroilhet, Lisa; Behbakht, Kian; Berchuck, Andrew; Berek, Jonathan S.; Chen, Lee May; Cristea, Mihaela; DeRosa, Marie; ElNaggar, Adam C.; Gershenson, David M.; Gray, Heidi J.; Hakam, Ardeshir; Jain, Angela; Leath, Charles A.; Liu, Joyce; Mahdi, Haider; Matei, Daniela; McHale, Michael; McLean, Karen; O'Malley, David M.; Penson, Richard T.; Percac-Lima, Sanja; Ratner, Elena; Remmenga, Steven W.; Sabbatini, Paul; Werner, Theresa L.; Zsiros, Emese; Burns, Jennifer L.; Engh, Anita M.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 17, No. 8, 01.01.2019, p. 896-909.

Research output: Contribution to journalReview article

Armstrong, DK, Alvarez, RD, Bakkum-Gamez, JN, Barroilhet, L, Behbakht, K, Berchuck, A, Berek, JS, Chen, LM, Cristea, M, DeRosa, M, ElNaggar, AC, Gershenson, DM, Gray, HJ, Hakam, A, Jain, A, Leath, CA, Liu, J, Mahdi, H, Matei, D, McHale, M, McLean, K, O'Malley, DM, Penson, RT, Percac-Lima, S, Ratner, E, Remmenga, SW, Sabbatini, P, Werner, TL, Zsiros, E, Burns, JL & Engh, AM 2019, 'Ovarian cancer, version 1.2019 featured updates to the nccn guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 17, no. 8, pp. 896-909. https://doi.org/10.6004/jnccn.2019.0039
Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A et al. Ovarian cancer, version 1.2019 featured updates to the nccn guidelines. JNCCN Journal of the National Comprehensive Cancer Network. 2019 Jan 1;17(8):896-909. https://doi.org/10.6004/jnccn.2019.0039
Armstrong, Deborah K. ; Alvarez, Ronald D. ; Bakkum-Gamez, Jamie N. ; Barroilhet, Lisa ; Behbakht, Kian ; Berchuck, Andrew ; Berek, Jonathan S. ; Chen, Lee May ; Cristea, Mihaela ; DeRosa, Marie ; ElNaggar, Adam C. ; Gershenson, David M. ; Gray, Heidi J. ; Hakam, Ardeshir ; Jain, Angela ; Leath, Charles A. ; Liu, Joyce ; Mahdi, Haider ; Matei, Daniela ; McHale, Michael ; McLean, Karen ; O'Malley, David M. ; Penson, Richard T. ; Percac-Lima, Sanja ; Ratner, Elena ; Remmenga, Steven W. ; Sabbatini, Paul ; Werner, Theresa L. ; Zsiros, Emese ; Burns, Jennifer L. ; Engh, Anita M. / Ovarian cancer, version 1.2019 featured updates to the nccn guidelines. In: JNCCN Journal of the National Comprehensive Cancer Network. 2019 ; Vol. 17, No. 8. pp. 896-909.
@article{be76194b29a2414fa62f8d99698e0355,
title = "Ovarian cancer, version 1.2019 featured updates to the nccn guidelines",
abstract = "Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living >5 years fromdiagnosis. Amajor challenge in treating ovarian cancer is that most patients have advanced disease at initial diagnosis. The best outcomes are observed in patients whose primary treatment includes complete resection of all visible disease plus combination platinum-based chemotherapy. Research efforts are focused on primary neoadjuvant treatments that may improve resectability, as well as systemic therapies providing improved long-term survival. These NCCN Guidelines Insights focus on recent updates to neoadjuvant chemotherapy recommendations, including the addition of hyperthermic intraperitoneal chemotherapy, and the role of PARP inhibitors and bevacizumab as maintenance therapy options in select patients who have completed primary chemotherapy.",
author = "Armstrong, {Deborah K.} and Alvarez, {Ronald D.} and Bakkum-Gamez, {Jamie N.} and Lisa Barroilhet and Kian Behbakht and Andrew Berchuck and Berek, {Jonathan S.} and Chen, {Lee May} and Mihaela Cristea and Marie DeRosa and ElNaggar, {Adam C.} and Gershenson, {David M.} and Gray, {Heidi J.} and Ardeshir Hakam and Angela Jain and Leath, {Charles A.} and Joyce Liu and Haider Mahdi and Daniela Matei and Michael McHale and Karen McLean and O'Malley, {David M.} and Penson, {Richard T.} and Sanja Percac-Lima and Elena Ratner and Remmenga, {Steven W.} and Paul Sabbatini and Werner, {Theresa L.} and Emese Zsiros and Burns, {Jennifer L.} and Engh, {Anita M.}",
year = "2019",
month = "1",
day = "1",
doi = "10.6004/jnccn.2019.0039",
language = "English (US)",
volume = "17",
pages = "896--909",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "8",

}

TY - JOUR

T1 - Ovarian cancer, version 1.2019 featured updates to the nccn guidelines

AU - Armstrong, Deborah K.

AU - Alvarez, Ronald D.

AU - Bakkum-Gamez, Jamie N.

AU - Barroilhet, Lisa

AU - Behbakht, Kian

AU - Berchuck, Andrew

AU - Berek, Jonathan S.

AU - Chen, Lee May

AU - Cristea, Mihaela

AU - DeRosa, Marie

AU - ElNaggar, Adam C.

AU - Gershenson, David M.

AU - Gray, Heidi J.

AU - Hakam, Ardeshir

AU - Jain, Angela

AU - Leath, Charles A.

AU - Liu, Joyce

AU - Mahdi, Haider

AU - Matei, Daniela

AU - McHale, Michael

AU - McLean, Karen

AU - O'Malley, David M.

AU - Penson, Richard T.

AU - Percac-Lima, Sanja

AU - Ratner, Elena

AU - Remmenga, Steven W.

AU - Sabbatini, Paul

AU - Werner, Theresa L.

AU - Zsiros, Emese

AU - Burns, Jennifer L.

AU - Engh, Anita M.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living >5 years fromdiagnosis. Amajor challenge in treating ovarian cancer is that most patients have advanced disease at initial diagnosis. The best outcomes are observed in patients whose primary treatment includes complete resection of all visible disease plus combination platinum-based chemotherapy. Research efforts are focused on primary neoadjuvant treatments that may improve resectability, as well as systemic therapies providing improved long-term survival. These NCCN Guidelines Insights focus on recent updates to neoadjuvant chemotherapy recommendations, including the addition of hyperthermic intraperitoneal chemotherapy, and the role of PARP inhibitors and bevacizumab as maintenance therapy options in select patients who have completed primary chemotherapy.

AB - Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living >5 years fromdiagnosis. Amajor challenge in treating ovarian cancer is that most patients have advanced disease at initial diagnosis. The best outcomes are observed in patients whose primary treatment includes complete resection of all visible disease plus combination platinum-based chemotherapy. Research efforts are focused on primary neoadjuvant treatments that may improve resectability, as well as systemic therapies providing improved long-term survival. These NCCN Guidelines Insights focus on recent updates to neoadjuvant chemotherapy recommendations, including the addition of hyperthermic intraperitoneal chemotherapy, and the role of PARP inhibitors and bevacizumab as maintenance therapy options in select patients who have completed primary chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85072145922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072145922&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2019.0039

DO - 10.6004/jnccn.2019.0039

M3 - Review article

C2 - 31390583

AN - SCOPUS:85072145922

VL - 17

SP - 896

EP - 909

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 8

ER -